Tumor-cell co-culture induced alternative activation of macrophages is modulated by interferons in vitro

Journal of Interferon and Cytokine Research

Volumn 32, Issue 4, 2012, Pages 169-177

  Müller Quernheim, Ulrike Carolin ^a   Potthast, Lars ^a   Müller Quernheim, Joachim ^a   Zissel, Gernot ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CCL18 PROTEIN; CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL POLARITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG FIBROSIS; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE;

CELL DIFFERENTIATION; CHEMOKINE CXCL10; CHEMOKINES, CC; COCULTURE TECHNIQUES; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE I; INTERFERON-GAMMA; INTERFERONS; MACROPHAGE ACTIVATION; MACROPHAGES; MONOCYTES; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859535781     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2011.0020     Document Type: Article

References (42)

1. Agarwala SS, Case S. 2010. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 15(3):236-245.
2. Albert RK, Embree LJ, McFeely JE, Hickstein DD. 1992. Expression and function of b 2 integrins on alveolar macrophages from human and nonhuman primates. Am J Respir Cell Mol Biol 7:182-189.
3. Biron CA. 2001. Interferons alpha and beta as immune regulators - a new look. Immunity 14(6):661-664. (Pubitemid 32592413)
4. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A. 2006. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107(5):2112-2122. (Pubitemid 43289397)
5. Blackwell SE, Krieg AM. 2003. CpG-A-induced monocyte IFN-gamma- inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. J Immunol 170(8):4061-4068. (Pubitemid 36428168)
6. Bradley SF, Vibhagool A, Kunkel SL, Kauffman CA. 1989. Monokine secretion in aging and protein malnutrition. J Leukoc Biol 45(6):510-514. (Pubitemid 19147358)
7. Coker RK, Laurent GJ. 1998. Pulmonary fibrosis: cytokines in the balance. Eur Respir J 11(6):1218-1221. (Pubitemid 28298579)
8. Fleetwood AJ, Dinh H, Cook AD, Hertzog PJ, Hamilton JA. 2009. GM-CSF- and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. J Leukoc Biol 86(2):411-421.
9. Giannopoulos A, Constantinides C, Fokaeas E, Stravodimos C, Giannopoulou M, Kyroudi A, Gounaris A. 2003. The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. Clin Cancer Res 9(15):5550-5558. (Pubitemid 37499474)
10. Gordon S. 2003. Alternative activation of macrophages. Nat Rev Immunol 3(1):23-35. (Pubitemid 37328697)
11. Grimshaw MJ, Balkwill FR. 2001. Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation - a potential mechanism. Eur J Immunol 31(2):480-489. (Pubitemid 32166603)
12. Gurujeyalakshmi G, Giri SN. 1995. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 21(5):791-808.
13. Halama N, Zoernig I, Jaeger D. 2010. Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J Oncol 2010:689893.
14. Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF, Beppu T, Baba H, Takeya M. 2010. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci 101(8):1913-1919.
15. Ho HH, Ivashkiv LB. 2006. Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 281(20):14111-14118. (Pubitemid 43848338)
16. Kaehler KC, Sondak VK, Schadendorf D, Hauschild A. 2010. Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. Eur J Cancer 46(1):41-46.
17. Kane A, Yang I. 2010. Interferon-gamma in brain tumor immunotherapy. Neurosurg Clin N Am 21(1):77-86.
18. Maher TM, Wells AU, Laurent GJ. 2007. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 30(5):835-839. (Pubitemid 351194784)
19. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549-555. (Pubitemid 35223554)
20. Martinez FO, Gordon S, Locati M, Mantovani A. 2006. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 177(10):7303-7311. (Pubitemid 44715100)
21. Martinez FO, Sica A, Mantovani A, Locati M. 2008. Macrophage activation and polarization. Front Biosci 13:453-461. (Pubitemid 351599757)
22. Miller CH, Maher SG, Young HA. 2009. Clinical use of interferon- gamma. Ann N Y Acad Sci 1182:69-79.
23. Mosser DM. 2003. The many faces of macrophage activation. J Leukoc Biol 73(2):209-212. (Pubitemid 36158295)
24. Mosser DM, Edwards JP. 2008. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8(12):958-969.
25. Narumi S, Hamilton TA. 1991. Inducible expression of murine IP-10 mRNA varies with the state of macrophage inflammatory activity. J Immunol 146(9):3038-3044.
26. Pechkovsky DV, Goldmann T, Ludwig C, Prasse A, Vollmer E, Muller-Quernheim J, Zissel G. 2005. CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II. Respir Res 6(1):75.
27. Pechkovsky DV, Prasse A, Kollert F, Engel KM, Dentler J, Luttmann W, Friedrich K, Muller-Quernheim J, Zissel G. 2010. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin Immunol 137(1):89-101.
28. Politz O, Kodelja V, Guillot P, Orfanos CE, Goerdt S. 2000. Pseudoexons and regulatory elements in the genomic sequence of the beta-chemokine, alternative macrophage activation-associated CC-chemokine (AMAC)-1. Cytokine 12(2):120-126. (Pubitemid 30449864)
29. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre- Bosquet N, Dormont D, Gras G. 2005. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 142(3):481-489. (Pubitemid 41719844)
30. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, Vollmer E, Muller-Quernheim J, Zissel G. 2006. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 173(7):781-792.
31. Prasse A, Pechkovsky DV, Toews GB, Schafer M, Eggeling S, Ludwig C, Germann M, Kollert F, Zissel G, Muller- Quernheim J. 2007. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum 56(5):1685-1693. (Pubitemid 46764100)
32. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, Francois E, Fumoleau P, Monnier A, Nooy M, Mignot L, Bugat R, Marques C, Mousseau M, Netter G, Maloisel F, Larbaoui S, Brandely M. 1996. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 14(2):343-350. (Pubitemid 26050993)
33. Rigo A, Gottardi M, Zamo A, Mauri P, Bonifacio M, Krampera M, Damiani E, Pizzolo G, Vinante F. 2010. Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer 9:273.
34. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. 2009. CCL2 and interleukin-6 promote survival of human CD11b + peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 284(49):34342-343454.
35. Saha B, Jyothi Prasanna S, Chandrasekar B, Nandi D. 2010. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 50(1):1-14.
36. Schoppmann SF, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvat R, Jakesz R, Birner P. 2006. VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery 139(6):839-846. (Pubitemid 43902914)
37. Schutyser E, Richmond A, Van Damme J. 2005. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 78(1):14-26. (Pubitemid 40979939)
38. Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, van Damme J, Mantovani A. 2000. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 164(2): 762-767. (Pubitemid 30043699)
39. Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L, Cohen-Hillel E, Shtabsky A, Ehrlich M, Meshel T, Keydar I, Ben-Baruch A. 2008. Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 44(1): 191-200.
40. Tsuda Y, Takahashi H, Kobayashi M, Hanafusa T, Herndon DN, Suzuki F. 2004. CCL2, a product of mice early after systemic inflammatory response syndrome (SIRS), induces alternatively activated macrophages capable of impairing antibacterial resistance of SIRS mice. J Leukoc Biol 76(2):368-373. (Pubitemid 39006950)
41. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E, Lokshin AE. 2007. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13(8):2422-2428. (Pubitemid 46698593)
42. Zhang J, Patel L, Pienta KJ. 2010. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci 95:31-53.